ERBB2 and gastric cancer: Twelve (30%) of 40 patients with tumor types other than gastric cancer achieved an objective response as defined by complete or partial response per RECIST version 1.1, with seven patients receiving trastuzumab and pertuzumab, four patients receiving trastuzumab with chemotherapy, and one patient receiving an HER2 antibody-drug conjugate.